FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2067452139> ?p ?o ?g. }

• W2067452139 endingPage "509" @default.
• W2067452139 startingPage "499" @default.
• W2067452139 abstract "Expression of macrophage migration inhibitory factor in human glomerulonephritis.BacκoundWe have recently demonstrated that macrophage migration inhibitory factor (MIF) plays a pathogenic role in experimental glomerulonephritis (GN). The aim of the current study was to investigate MIF expression in human GN.MethodsMIF expression was examined by in situ hybridization and immunohistochemistry staining in 65 biopsies from a variety of glomerulonephridities.ResultsThere is constitutive expression of MIF mRNA and protein in normal human kidney that is largely restricted to tubular epithelial cells and to some glomerular epithelial cells. There was little change in the pattern of MIF expression in nonproliferative forms of GN such as minimal change disease and membranous GN. However, there was a marked increase in both glomerular and tubular MIF expression in proliferative forms of GN, including focal segmental glomerulosclerosis (FGS), lupus nephritis, crescentic GN, and mesangiocapillary proliferative GN. The prominent macrophage and T-cell infiltrate in these diseases were largely restricted to areas with marked up-regulation of MIF expression, contributing to glomerular hypercellularity, glomerular focal segmental lesions, crescent formation, tubulitis, and granulomatous lesions. De novo MIF expression was evident in glomerular endothelial cells and mesangial cells in proliferative forms of GN. In addition, many infiltrating macrophages and T cells showed MIF mRNA and protein expression. Quantitative analysis found that increased glomerular and tubular MIF expression gave a highly significant correlation with macrophage and T-cell accumulation, the severity of histologic lesions, and the loss of creatinine clearance.ConclusionsRenal MIF expression is markedly up-regulated in proliferative forms of human GN, and this correlates with leukocyte infiltration, histologic damage, and renal function impairment. These results suggest that MIF may be an important mediator of renal injury in progressive forms of human GN. Based on these findings, together with the known pathogenic role of MIF in experimental GN, we propose that MIF is an attractive therapeutic target in the treatment of progressive forms of GN. Expression of macrophage migration inhibitory factor in human glomerulonephritis. We have recently demonstrated that macrophage migration inhibitory factor (MIF) plays a pathogenic role in experimental glomerulonephritis (GN). The aim of the current study was to investigate MIF expression in human GN. MIF expression was examined by in situ hybridization and immunohistochemistry staining in 65 biopsies from a variety of glomerulonephridities. There is constitutive expression of MIF mRNA and protein in normal human kidney that is largely restricted to tubular epithelial cells and to some glomerular epithelial cells. There was little change in the pattern of MIF expression in nonproliferative forms of GN such as minimal change disease and membranous GN. However, there was a marked increase in both glomerular and tubular MIF expression in proliferative forms of GN, including focal segmental glomerulosclerosis (FGS), lupus nephritis, crescentic GN, and mesangiocapillary proliferative GN. The prominent macrophage and T-cell infiltrate in these diseases were largely restricted to areas with marked up-regulation of MIF expression, contributing to glomerular hypercellularity, glomerular focal segmental lesions, crescent formation, tubulitis, and granulomatous lesions. De novo MIF expression was evident in glomerular endothelial cells and mesangial cells in proliferative forms of GN. In addition, many infiltrating macrophages and T cells showed MIF mRNA and protein expression. Quantitative analysis found that increased glomerular and tubular MIF expression gave a highly significant correlation with macrophage and T-cell accumulation, the severity of histologic lesions, and the loss of creatinine clearance. Renal MIF expression is markedly up-regulated in proliferative forms of human GN, and this correlates with leukocyte infiltration, histologic damage, and renal function impairment. These results suggest that MIF may be an important mediator of renal injury in progressive forms of human GN. Based on these findings, together with the known pathogenic role of MIF in experimental GN, we propose that MIF is an attractive therapeutic target in the treatment of progressive forms of GN." @default.
• W2067452139 created "2016-06-24" @default.
• W2067452139 creator A5013582611 @default.
• W2067452139 creator A5023747148 @default.
• W2067452139 creator A5029456441 @default.
• W2067452139 creator A5031622675 @default.
• W2067452139 creator A5042220634 @default.
• W2067452139 creator A5061472855 @default.
• W2067452139 creator A5065787721 @default.
• W2067452139 creator A5071238542 @default.
• W2067452139 creator A5071246588 @default.
• W2067452139 date "2000-10-01" @default.
• W2067452139 modified "2023-10-16" @default.
• W2067452139 title "Expression of macrophage migration inhibitory factor in human glomerulonephritis" @default.
• W2067452139 cites W132316020 @default.
• W2067452139 cites W1510912973 @default.
• W2067452139 cites W1964668568 @default.
• W2067452139 cites W1969378161 @default.
• W2067452139 cites W1977448440 @default.
• W2067452139 cites W1986837253 @default.
• W2067452139 cites W1995910069 @default.
• W2067452139 cites W2001634895 @default.
• W2067452139 cites W2009462086 @default.
• W2067452139 cites W2012103481 @default.
• W2067452139 cites W2024977803 @default.
• W2067452139 cites W2040336985 @default.
• W2067452139 cites W2042779674 @default.
• W2067452139 cites W2049628599 @default.
• W2067452139 cites W2062824264 @default.
• W2067452139 cites W2066868766 @default.
• W2067452139 cites W2079651752 @default.
• W2067452139 cites W2082791667 @default.
• W2067452139 cites W2088954042 @default.
• W2067452139 cites W2090056328 @default.
• W2067452139 cites W2103653250 @default.
• W2067452139 cites W2103926327 @default.
• W2067452139 cites W2121591560 @default.
• W2067452139 cites W2122151701 @default.
• W2067452139 cites W2126600660 @default.
• W2067452139 cites W2141991660 @default.
• W2067452139 cites W2146058212 @default.
• W2067452139 cites W2152058417 @default.
• W2067452139 cites W2316978300 @default.
• W2067452139 cites W39926608 @default.
• W2067452139 cites W4322387796 @default.
• W2067452139 doi "https://doi.org/10.1046/j.1523-1755.2000.00869.x" @default.
• W2067452139 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10652026" @default.
• W2067452139 hasPublicationYear "2000" @default.
• W2067452139 type Work @default.
• W2067452139 sameAs 2067452139 @default.
• W2067452139 citedByCount "165" @default.
• W2067452139 countsByYear W20674521392012 @default.
• W2067452139 countsByYear W20674521392013 @default.
• W2067452139 countsByYear W20674521392014 @default.
• W2067452139 countsByYear W20674521392015 @default.
• W2067452139 countsByYear W20674521392016 @default.
• W2067452139 countsByYear W20674521392017 @default.
• W2067452139 countsByYear W20674521392018 @default.
• W2067452139 countsByYear W20674521392019 @default.
• W2067452139 countsByYear W20674521392020 @default.
• W2067452139 countsByYear W20674521392021 @default.
• W2067452139 countsByYear W20674521392022 @default.
• W2067452139 countsByYear W20674521392023 @default.
• W2067452139 crossrefType "journal-article" @default.
• W2067452139 hasAuthorship W2067452139A5013582611 @default.
• W2067452139 hasAuthorship W2067452139A5023747148 @default.
• W2067452139 hasAuthorship W2067452139A5029456441 @default.
• W2067452139 hasAuthorship W2067452139A5031622675 @default.
• W2067452139 hasAuthorship W2067452139A5042220634 @default.
• W2067452139 hasAuthorship W2067452139A5061472855 @default.
• W2067452139 hasAuthorship W2067452139A5065787721 @default.
• W2067452139 hasAuthorship W2067452139A5071238542 @default.
• W2067452139 hasAuthorship W2067452139A5071246588 @default.
• W2067452139 hasBestOaLocation W20674521391 @default.
• W2067452139 hasConcept C104177226 @default.
• W2067452139 hasConcept C104317684 @default.
• W2067452139 hasConcept C126322002 @default.
• W2067452139 hasConcept C134018914 @default.
• W2067452139 hasConcept C142724271 @default.
• W2067452139 hasConcept C150194340 @default.
• W2067452139 hasConcept C202751555 @default.
• W2067452139 hasConcept C203014093 @default.
• W2067452139 hasConcept C2777390665 @default.
• W2067452139 hasConcept C2778690821 @default.
• W2067452139 hasConcept C2779134260 @default.
• W2067452139 hasConcept C2779244956 @default.
• W2067452139 hasConcept C2779561371 @default.
• W2067452139 hasConcept C2779912601 @default.
• W2067452139 hasConcept C2780091579 @default.
• W2067452139 hasConcept C2780368995 @default.
• W2067452139 hasConcept C55493867 @default.
• W2067452139 hasConcept C71924100 @default.
• W2067452139 hasConcept C81439078 @default.
• W2067452139 hasConcept C86803240 @default.
• W2067452139 hasConceptScore W2067452139C104177226 @default.
• W2067452139 hasConceptScore W2067452139C104317684 @default.
• W2067452139 hasConceptScore W2067452139C126322002 @default.
• W2067452139 hasConceptScore W2067452139C134018914 @default.

• next